Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 412 entries
Sorted by: Best Match Show Resources per page
Designing Organic Electron Transport Materials for Stable and Efficient Performance of Perovskite Solar Cells: A Theoretical Study.

ACS omega

Kumar A, Ojha SK, Vyas N, Ojha AK.
PMID: 33748622
ACS Omega. 2021 Mar 01;6(10):7086-7093. doi: 10.1021/acsomega.1c00062. eCollection 2021 Mar 16.

In this article, electron transporting layer (ETL) materials are designed to enhance the performance and stability of methyl ammonium lead iodide (MAPbI

Cite
Kumar A, Ojha SK, Vyas N, et al. Designing Organic Electron Transport Materials for Stable and Efficient Performance of Perovskite Solar Cells: A Theoretical Study. ACS Omega. 2021;6(10):7086-7093doi: 10.1021/acsomega.1c00062.
Kumar, A., Ojha, S. K., Vyas, N., & Ojha, A. K. (2021). Designing Organic Electron Transport Materials for Stable and Efficient Performance of Perovskite Solar Cells: A Theoretical Study. ACS omega, 6(10), 7086-7093. https://doi.org/10.1021/acsomega.1c00062
Kumar, Aditya, et al. "Designing Organic Electron Transport Materials for Stable and Efficient Performance of Perovskite Solar Cells: A Theoretical Study." ACS omega vol. 6,10 (2021): 7086-7093. doi: https://doi.org/10.1021/acsomega.1c00062
Kumar A, Ojha SK, Vyas N, Ojha AK. Designing Organic Electron Transport Materials for Stable and Efficient Performance of Perovskite Solar Cells: A Theoretical Study. ACS Omega. 2021 Mar 01;6(10):7086-7093. doi: 10.1021/acsomega.1c00062. eCollection 2021 Mar 16. PMID: 33748622; PMCID: PMC7970561.
Copy Download .nbib Format: NLM
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.

ESMO open

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT.
PMID: 34715570
ESMO Open. 2021 Oct 26;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26.

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic MCC (mMCC), based on...

Cite
D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021;6(6):100290doi: 10.1016/j.esmoop.2021.100290.
D'Angelo, S. P., Bhatia, S., Brohl, A. S., Hamid, O., Mehnert, J. M., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Xiong, H., Guezel, G., & Nghiem, P. T. (2021). Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO open, 6(6), 100290. https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo, S P, et al. "Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up." ESMO open vol. 6,6 (2021): 100290. doi: https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021 Oct 26;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26. PMID: 34715570; PMCID: PMC8564559.
Copy Download .nbib Format: NLM
Modish Designation of Hollow-Tubular rGO-NiMoO.

ACS applied materials & interfaces

Acharya J, Ojha GP, Kim BS, Pant B, Park M.
PMID: 33844490
ACS Appl Mater Interfaces. 2021 Apr 21;13(15):17487-17500. doi: 10.1021/acsami.1c00137. Epub 2021 Apr 12.

The scrupulous designation of hollow and porous electroactive materials incorporating prolific redox-active polyphase transition-metal oxide decorated with polyphase transition-metal sulfide onto rGO (reduced graphene oxide)-supported conductive substrate has never been an easy task due to the very good coordination...

Cite
Acharya J, Ojha GP, Kim BS, et al. Modish Designation of Hollow-Tubular rGO-NiMoO. ACS Appl Mater Interfaces. 2021;13(15):17487-17500doi: 10.1021/acsami.1c00137.
Acharya, J., Ojha, G. P., Kim, B. S., Pant, B., & Park, M. (2021). Modish Designation of Hollow-Tubular rGO-NiMoO. ACS applied materials & interfaces, 13(15), 17487-17500. https://doi.org/10.1021/acsami.1c00137
Acharya, Jiwan, et al. "Modish Designation of Hollow-Tubular rGO-NiMoO." ACS applied materials & interfaces vol. 13,15 (2021): 17487-17500. doi: https://doi.org/10.1021/acsami.1c00137
Acharya J, Ojha GP, Kim BS, Pant B, Park M. Modish Designation of Hollow-Tubular rGO-NiMoO. ACS Appl Mater Interfaces. 2021 Apr 21;13(15):17487-17500. doi: 10.1021/acsami.1c00137. Epub 2021 Apr 12. PMID: 33844490.
Copy Download .nbib Format: NLM
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research

Annala M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, Beja K, Sipola J, Warner EW, Herberts C, Wong A, Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW.
PMID: 34083234
Clin Cancer Res. 2021 Aug 15;27(16):4610-4623. doi: 10.1158/1078-0432.CCR-21-1625. Epub 2021 Jun 03.

PURPOSE: Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance.EXPERIMENTAL DESIGN: We collected 458 serial plasma cell-free DNA samples at baseline...

Cite
Annala M, Taavitsainen S, Khalaf DJ, et al. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021;27(16):4610-4623doi: 10.1158/1078-0432.CCR-21-1625.
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Eigl, B. J., Kollmansberger, C. K., Nykter, M., Gleave, M. E., Chi, K. N., & Wyatt, A. W. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4610-4623. https://doi.org/10.1158/1078-0432.CCR-21-1625
Annala, Matti, et al. "Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4610-4623. doi: https://doi.org/10.1158/1078-0432.CCR-21-1625
Annala M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, Beja K, Sipola J, Warner EW, Herberts C, Wong A, Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021 Aug 15;27(16):4610-4623. doi: 10.1158/1078-0432.CCR-21-1625. Epub 2021 Jun 03. PMID: 34083234.
Copy Download .nbib Format: NLM
Impact of prognostic factor distributions on mortality disparities for socioeconomically disadvantaged cancer patients.

Annals of epidemiology

Lu Y, Gehr AW, Narra K, Lingam A, Ghabach B, Meadows RJ, Ojha RP.
PMID: 34601096
Ann Epidemiol. 2022 Jan;65:31-37. doi: 10.1016/j.annepidem.2021.09.014. Epub 2021 Oct 01.

PURPOSE: We aimed to assess whether differences in the distributions of prognostic factors explain reported mortality disparities between urban safety-net and Surveillance, Epidemiology, and End Results (SEER) cancer populations.METHODS: We used data from SEER and a safety-net cancer center...

Cite
Lu Y, Gehr AW, Narra K, et al. Impact of prognostic factor distributions on mortality disparities for socioeconomically disadvantaged cancer patients. Ann Epidemiol. 2021;65:31-37doi: 10.1016/j.annepidem.2021.09.014.
Lu, Y., Gehr, A. W., Narra, K., Lingam, A., Ghabach, B., Meadows, R. J., & Ojha, R. P. (2022). Impact of prognostic factor distributions on mortality disparities for socioeconomically disadvantaged cancer patients. Annals of epidemiology, 6531-37. https://doi.org/10.1016/j.annepidem.2021.09.014
Lu, Yan, et al. "Impact of prognostic factor distributions on mortality disparities for socioeconomically disadvantaged cancer patients." Annals of epidemiology vol. 65 (2022): 31-37. doi: https://doi.org/10.1016/j.annepidem.2021.09.014
Lu Y, Gehr AW, Narra K, Lingam A, Ghabach B, Meadows RJ, Ojha RP. Impact of prognostic factor distributions on mortality disparities for socioeconomically disadvantaged cancer patients. Ann Epidemiol. 2022 Jan;65:31-37. doi: 10.1016/j.annepidem.2021.09.014. Epub 2021 Oct 01. PMID: 34601096.
Copy Download .nbib Format: NLM
From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.

Molecular aspects of medicine

Pandey M, Ojha D, Bansal S, Rode AB, Chawla G.
PMID: 34332771
Mol Aspects Med. 2021 Oct;81:101003. doi: 10.1016/j.mam.2021.101003. Epub 2021 Jul 28.

The functional and structural versatility of Ribonucleic acids (RNAs) makes them ideal candidates for overcoming the limitations imposed by small molecule-based drugs. Hence, RNA-based biopharmaceuticals such as messenger RNA (mRNA) vaccines, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA...

Cite
Pandey M, Ojha D, Bansal S, et al. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med. 2021;81:101003doi: 10.1016/j.mam.2021.101003.
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021). From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular aspects of medicine, 81101003. https://doi.org/10.1016/j.mam.2021.101003
Pandey, Manish, et al. "From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases." Molecular aspects of medicine vol. 81 (2021): 101003. doi: https://doi.org/10.1016/j.mam.2021.101003
Pandey M, Ojha D, Bansal S, Rode AB, Chawla G. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med. 2021 Oct;81:101003. doi: 10.1016/j.mam.2021.101003. Epub 2021 Jul 28. PMID: 34332771.
Copy Download .nbib Format: NLM
Serum biochemical parameters as a surrogate marker for chest computed tomography in children with COVID-19.

Future virology

Das KM, Singh R, Subramanya S, Ojha SK, Almansoori T, Gokhale D, Alkoteesh JA.
PMID: 34539810
Future Virol. 2021 Sep;16(9):601-609. doi: 10.2217/fvl-2021-0118. Epub 2021 Sep 02.

AIM: This study aimed to investigate whether serum biochemical parameters can be used as a surrogate for chest computed tomography (CT) in the diagnosis of COVID-19 in pediatric patients.MATERIALS & METHODS: We evaluated potential associations between various serum biochemical...

Cite
Das KM, Singh R, Subramanya S, et al. Serum biochemical parameters as a surrogate marker for chest computed tomography in children with COVID-19. Future Virol. 2021;16(9):601-609doi: 10.2217/fvl-2021-0118.
Das, K. M., Singh, R., Subramanya, S., Ojha, S. K., Almansoori, T., Gokhale, D., & Alkoteesh, J. A. (2021). Serum biochemical parameters as a surrogate marker for chest computed tomography in children with COVID-19. Future virology, 16(9), 601-609. https://doi.org/10.2217/fvl-2021-0118
Das, Karuna M, et al. "Serum biochemical parameters as a surrogate marker for chest computed tomography in children with COVID-19." Future virology vol. 16,9 (2021): 601-609. doi: https://doi.org/10.2217/fvl-2021-0118
Das KM, Singh R, Subramanya S, Ojha SK, Almansoori T, Gokhale D, Alkoteesh JA. Serum biochemical parameters as a surrogate marker for chest computed tomography in children with COVID-19. Future Virol. 2021 Sep;16(9):601-609. doi: 10.2217/fvl-2021-0118. Epub 2021 Sep 02. PMID: 34539810; PMCID: PMC8439343.
Copy Download .nbib Format: NLM
Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease.

Pharmaceutics

Nigam AK, Ojha AA, Li JG, Shi D, Bhatnagar V, Nigam KB, Abagyan R, Nigam SK.
PMID: 34684013
Pharmaceutics. 2021 Oct 18;13(10). doi: 10.3390/pharmaceutics13101720.

In patients with liver or kidney disease, it is especially important to consider the routes of metabolism and elimination of small-molecule pharmaceuticals. Once in the blood, numerous drugs are taken up by the liver for metabolism and/or biliary elimination,...

Cite
Nigam AK, Ojha AA, Li JG, et al. Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics. 2021;13(10)doi: 10.3390/pharmaceutics13101720.
Nigam, A. K., Ojha, A. A., Li, J. G., Shi, D., Bhatnagar, V., Nigam, K. B., Abagyan, R., & Nigam, S. K. (2021). Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics, 13(10), . https://doi.org/10.3390/pharmaceutics13101720
Nigam, Anisha K, et al. "Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease." Pharmaceutics vol. 13,10 (2021). doi: https://doi.org/10.3390/pharmaceutics13101720
Nigam AK, Ojha AA, Li JG, Shi D, Bhatnagar V, Nigam KB, Abagyan R, Nigam SK. Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics. 2021 Oct 18;13(10). doi: 10.3390/pharmaceutics13101720. PMID: 34684013; PMCID: PMC8538396.
Copy Download .nbib Format: NLM
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.

ESMO open

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT.
PMID: 34715570
ESMO Open. 2021 Oct 26;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26.

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic MCC (mMCC), based on...

Cite
D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021;6(6):100290doi: 10.1016/j.esmoop.2021.100290.
D'Angelo, S. P., Bhatia, S., Brohl, A. S., Hamid, O., Mehnert, J. M., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Xiong, H., Guezel, G., & Nghiem, P. T. (2021). Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO open, 6(6), 100290. https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo, S P, et al. "Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up." ESMO open vol. 6,6 (2021): 100290. doi: https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021 Oct 26;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26. PMID: 34715570; PMCID: PMC8564559.
Copy Download .nbib Format: NLM
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.

ESMO open

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT.
PMID: 34715570
ESMO Open. 2021 Dec;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26.

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed death-ligand 1 (PD-L1)] became the first approved treatment for patients with metastatic MCC (mMCC), based on...

Cite
D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021;6(6):100290doi: 10.1016/j.esmoop.2021.100290.
D'Angelo, S. P., Bhatia, S., Brohl, A. S., Hamid, O., Mehnert, J. M., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Xiong, H., Guezel, G., & Nghiem, P. T. (2021). Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO open, 6(6), 100290. https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo, S P, et al. "Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up." ESMO open vol. 6,6 (2021): 100290. doi: https://doi.org/10.1016/j.esmoop.2021.100290
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021 Dec;6(6):100290. doi: 10.1016/j.esmoop.2021.100290. Epub 2021 Oct 26. PMID: 34715570; PMCID: PMC8564559.
Copy Download .nbib Format: NLM
Recent Progress in Metal-Organic Framework-Derived Nanostructures in the Removal of Volatile Organic Compounds.

Molecules (Basel, Switzerland)

Bhattarai DP, Pant B, Acharya J, Park M, Ojha GP.
PMID: 34443537
Molecules. 2021 Aug 16;26(16). doi: 10.3390/molecules26164948.

Air is the most crucial and life-supporting input from nature to the living beings of the planet. The composition and quality of air significantly affects human health, either directly or indirectly. The presence of some industrially released gases, small...

Cite
Bhattarai DP, Pant B, Acharya J, et al. Recent Progress in Metal-Organic Framework-Derived Nanostructures in the Removal of Volatile Organic Compounds. Molecules. 2021;26(16)doi: 10.3390/molecules26164948.
Bhattarai, D. P., Pant, B., Acharya, J., Park, M., & Ojha, G. P. (2021). Recent Progress in Metal-Organic Framework-Derived Nanostructures in the Removal of Volatile Organic Compounds. Molecules (Basel, Switzerland), 26(16), . https://doi.org/10.3390/molecules26164948
Bhattarai, Deval Prasad, et al. "Recent Progress in Metal-Organic Framework-Derived Nanostructures in the Removal of Volatile Organic Compounds." Molecules (Basel, Switzerland) vol. 26,16 (2021). doi: https://doi.org/10.3390/molecules26164948
Bhattarai DP, Pant B, Acharya J, Park M, Ojha GP. Recent Progress in Metal-Organic Framework-Derived Nanostructures in the Removal of Volatile Organic Compounds. Molecules. 2021 Aug 16;26(16). doi: 10.3390/molecules26164948. PMID: 34443537; PMCID: PMC8400575.
Copy Download .nbib Format: NLM
Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome.

Annals of Indian Academy of Neurology

Pujari SS, Kulkarni RV, Nadgir DB, Ojha PK, Nagendra S, Aglave V, Nadgir RD, Sant H, Palasdeokar N, Nirhale S, Bandishti S.
PMID: 33911382
Ann Indian Acad Neurol. 2021 Jan-Feb;24(1):69-77. doi: 10.4103/aian.AIAN_627_19. Epub 2020 Mar 03.

BACKGROUND: Discovery of serum myelin oligodendrocyte glycoprotein (MOG) antibody testing in demyelination segregated MOG-IgG disease from AQ-4-IgG positive NMOSD.AIMS: To study clinico-radiological manifestations, pattern of laboratory and electrophysiological investigations and response to treatment through follow up in MOG-IgG positive...

Cite
Pujari SS, Kulkarni RV, Nadgir DB, et al. Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome. Ann Indian Acad Neurol. 2020;24(1):69-77doi: 10.4103/aian.AIAN_627_19.
Pujari, S. S., Kulkarni, R. V., Nadgir, D. B., Ojha, P. K., Nagendra, S., Aglave, V., Nadgir, R. D., Sant, H., Palasdeokar, N., Nirhale, S., & Bandishti, S. (2021). Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome. Annals of Indian Academy of Neurology, 24(1), 69-77. https://doi.org/10.4103/aian.AIAN_627_19
Pujari, Shripad S, et al. "Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome." Annals of Indian Academy of Neurology vol. 24,1 (2021): 69-77. doi: https://doi.org/10.4103/aian.AIAN_627_19
Pujari SS, Kulkarni RV, Nadgir DB, Ojha PK, Nagendra S, Aglave V, Nadgir RD, Sant H, Palasdeokar N, Nirhale S, Bandishti S. Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome. Ann Indian Acad Neurol. 2021 Jan-Feb;24(1):69-77. doi: 10.4103/aian.AIAN_627_19. Epub 2020 Mar 03. PMID: 33911382; PMCID: PMC8061523.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 412 entries